Skip to main content
Probi logo

Probi — Investor Relations & Filings

Ticker · PROB ISIN · SE0001280355 LEI · 5493004CJOCT273MU397 ST Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2014-08-19 Interim / Quarterly Rep…
Country SE Sweden
Listing ST PROB

About Probi

https://www.probi.com/

Probi is a global biotics company specializing in the research, development, and manufacturing of clinically documented probiotic strains. The company provides biotic solutions for dietary supplements and functional foods, targeting specific health needs across various life stages. Its portfolio addresses key areas such as digestive, immune, mental, and metabolic health, alongside specialized formulations for women, children, and healthy aging. Probi's offerings are founded on extensive scientific research and clinical studies to ensure proven efficacy in supporting human health.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Probi AB covering the period 2014-01-01 to 2014-06-30. It contains detailed financial statements, including income statements, cash flow analysis, segment reporting, and management commentary on business performance. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2014
2014-08-19 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 1% confidence The document is titled 'PROBI AB INTERIM REPORT 1 January 2014 - 30 June 2014'. It contains comprehensive financial statements, including net sales, operating profit, cash flow, and segment information for the specified interim period. It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H2 2014
2014-08-19 English
Ytterligare en studie visar att probiotika från Probi kan öka järnupptaget hos kvinnor i fertil ålder
Regulatory Filings Classification · 1% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces new study results regarding the effect of a probiotic strain on iron absorption. It includes quotes from the CEO, background information, study details, and contact information for media inquiries. This format is characteristic of an initial announcement of financial or significant operational news, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) if it's a significant, non-standard announcement. Since it is not a formal financial report (like 10-K or IR), nor a transcript (CT), nor a specific management/board change (MANG), nor a dividend notice (DIV), it functions as a general corporate announcement. Given the options, and since it is a press release announcing scientific/product development news rather than a formal regulatory filing required by securities law (like a 10-K or DVA), it fits best under the general regulatory/corporate announcement category, RNS, or potentially ER if the company views product news as part of its periodic updates, but ER is usually strictly financial results. Given the content is scientific validation leading to future product launch plans, RNS (Regulatory Filings/General Announcement) is the most appropriate catch-all for significant, non-standard corporate news releases.
2014-07-17 Swedish
Another study demonstrates that probiotics from Probi can enhance iron absorption among women of childbearing potential
Environmental & Social Information Classification · 1% confidence The document is titled "PRESS RELEASE" and announces new scientific findings regarding a probiotic strain's effect on iron absorption. It discusses research results, background information, and future plans for product launch. This type of announcement, which communicates key business or scientific developments outside of mandatory financial reporting forms (like 10-K or ER), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific corporate action (DIV, CAP, DIRS), nor a presentation (IP), the most appropriate general category for a press release announcing scientific/business progress is 'Regulatory Filings' (RNS), which serves as a broad category for non-standard regulatory disclosures or news releases. Given the document length (3809 chars) and content, it is the primary announcement itself, not an announcement *of* a report, so RPA is not applicable. It is a general business/scientific update.
2014-07-17 English
Probi lanserar Probi Digestis® i Turkiet
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by "PRESSMEDDELANDE") announcing a new distribution agreement for the product Probi Digestis® in Turkey, effective Q3 2014. It details a business development/partnership (distribution agreement) rather than reporting financial results (ER, IR, 10-K), management changes (MANG), or shareholder votes (DVA). It is a specific business announcement concerning market expansion and partnership. This type of announcement, which is not explicitly covered by the more specific codes (like 10-K, ER, MANG, DIV, etc.), falls best under the general regulatory announcement category, RNS, as it is a material event disclosed to the public market, or potentially a general business update. Given the options, RNS (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for a significant, non-financial, non-governance business development announcement that doesn't fit the other specific categories like M&A (TAR) or Capital Change (CAP). Since it is a formal announcement required by market rules ("Denna information är sådan som Probi AB ska offentliggöra enligt lagen om värdepappersmarknaden"), RNS is the best fit.
2014-05-06 Swedish
Probi to launch Probi Digestis® in Turkey
Regulatory Filings Classification · 1% confidence The document is titled 'PRESS RELEASE' and announces a new distribution agreement for a product launch in Turkey. It contains forward-looking statements about market entry and cooperation, and concludes with contact information and 'ABOUT' sections for both companies involved. Crucially, it states: 'The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.' This indicates a mandatory regulatory disclosure, but it is not a formal financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or SHA). Since it is a general, mandatory disclosure about a business development (a distribution agreement/market entry) that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS). The document length (3324 chars) is short, suggesting it is an announcement rather than a full report.
2014-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.